雷珠单抗治疗湿性年龄相关性黄斑变性的视力改善与黄斑形态学变化相关性分析(1)
摘 要：目的 分析雷珠单抗治疗湿性年龄相关性黄斑变性的视力改善和黄斑形态学变化之间的相关性。方法 选取2014年1月～2016年2月在西安交通大学第一附属医院行雷珠单抗治疗的湿性年龄相关性黄斑变性患者43例(1眼/例)。观察治疗前后最佳矫正视力(BCVA)、黄斑中心凹厚度(CMT)及黄斑病变面积。分析视力改善与黄斑形态学变化之间的相关性。结果 治疗3个月后，BCVA升高字母数(8.93±5.70)个，CMT下降(115.35±56.24)μm，黄斑病变面积减少(2.04±0.65)mm2。治疗3个月后，BCVA变化与CMT变化之间无相关性(r=-0.170，P>0.05)；BCVA变化与黄斑病变面积改变之间无相关性(r=-0.101，P>0.05)。结论 雷珠单抗治疗湿性AMD具有较好疗效，提高患者视力，改善黄斑形态学，视力改善与黄斑形态学变化之间无相关性。
关键词：年龄相关性黄斑变性；雷珠单抗；最佳矫正视力；黄斑形态学
中图分类号：R779.6 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.22.031
, http://www.100md.com
文章编号：1006-1959(2018)22-0113-03
Correlation between Visual Acuity Improvement and Morphological Changes of Macular in Treatment of Wet Age-related Macular Degeneration with Ranibizumab
WANG Xiao-tang，XIE An-ming
(Department of Ophthalmology，the First Affiliated Hospital of Xi'an Jiaotong University，Xi'an 710061，Shaanxi，China)
Abstract：Objective To retrospectively analyze the correlations between visual acuity and macular morphology after ranibizumab therapy for the wet age-related macular degeneration. Methods From January 2014 to February 2016， 43 patients (1 eye/case) of wet age-related macular degeneration treated with ranibizumab in the First Affiliated Hospital of Xi'an Jiaotong University were selected. The best corrected visual acuity (BCVA)， macular foveal thickness (CMT) and macular degeneration area were observed before and after treatment. Analyze the correlation between visual acuity improvement and morphological changes of the macula. Results After 3 months of treatment， the number of letters in BCVA increased (8.93±5.70)， the CMT decreased (115.35±56.24)μm， and the area of macular lesion decreased (2.04±0.65) mm2. There was no correlation between BCVA changes and CMT changes after 3 months of treatment (r=-0.170， P>0.05)； there was no correlation between BCVA changes and macular lesions (r=-0.101， P>0.05). Conclusion Ralmuzumab has a good effect in the treatment of wet AMD， improving vision and improving macular morphology， and there is no correlation between visual acuity improvement and macular morphological changes.
, 百拇医药
Key words：Age-related macular degeneration；Ranibizumab；Best corrected visual acuity；Macular morphology
年齡相关性黄斑变性(age-related macular degeneration，AMD)是一种慢性进展性的视网膜退行性病变，是50岁以上人群中的主要致盲性眼病，预计到2040年全球患病率近3亿人[1]。AMD分为干性(占85%～90%)和湿性(占10%～15%)两种类型。由于湿性AMD造成的视力损害大于干性AMD，故目前治疗主要针对前者。湿性AMD病理改变是脉络膜新生血管的形成，由血液、渗出液和细胞外液形成的脉络膜-视网膜色素上皮细胞-视网膜混合物堆积导致黄斑增厚[2]。血管内皮生长因子在脉络膜新生血管形成中起重要作用[3]。因此，抗血管内皮生长因子靶向治疗湿性AMD具有显著疗效[4]。2006年美国食品与药品管理局批准雷珠单抗用于治疗湿性AMD，2012年中国国家药监局批准其用于治疗湿性AMD。本研究使用雷珠单抗治疗湿性AMD后取得较好效果，并分析视力改善与黄斑形态学变化之间的相关性，现报告如下。, http://www.100md.com(王小堂 谢安明)
关键词：年龄相关性黄斑变性；雷珠单抗；最佳矫正视力；黄斑形态学
中图分类号：R779.6 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.22.031
, http://www.100md.com
文章编号：1006-1959(2018)22-0113-03
Correlation between Visual Acuity Improvement and Morphological Changes of Macular in Treatment of Wet Age-related Macular Degeneration with Ranibizumab
WANG Xiao-tang，XIE An-ming
(Department of Ophthalmology，the First Affiliated Hospital of Xi'an Jiaotong University，Xi'an 710061，Shaanxi，China)
Abstract：Objective To retrospectively analyze the correlations between visual acuity and macular morphology after ranibizumab therapy for the wet age-related macular degeneration. Methods From January 2014 to February 2016， 43 patients (1 eye/case) of wet age-related macular degeneration treated with ranibizumab in the First Affiliated Hospital of Xi'an Jiaotong University were selected. The best corrected visual acuity (BCVA)， macular foveal thickness (CMT) and macular degeneration area were observed before and after treatment. Analyze the correlation between visual acuity improvement and morphological changes of the macula. Results After 3 months of treatment， the number of letters in BCVA increased (8.93±5.70)， the CMT decreased (115.35±56.24)μm， and the area of macular lesion decreased (2.04±0.65) mm2. There was no correlation between BCVA changes and CMT changes after 3 months of treatment (r=-0.170， P>0.05)； there was no correlation between BCVA changes and macular lesions (r=-0.101， P>0.05). Conclusion Ralmuzumab has a good effect in the treatment of wet AMD， improving vision and improving macular morphology， and there is no correlation between visual acuity improvement and macular morphological changes.
, 百拇医药
Key words：Age-related macular degeneration；Ranibizumab；Best corrected visual acuity；Macular morphology
年齡相关性黄斑变性(age-related macular degeneration，AMD)是一种慢性进展性的视网膜退行性病变，是50岁以上人群中的主要致盲性眼病，预计到2040年全球患病率近3亿人[1]。AMD分为干性(占85%～90%)和湿性(占10%～15%)两种类型。由于湿性AMD造成的视力损害大于干性AMD，故目前治疗主要针对前者。湿性AMD病理改变是脉络膜新生血管的形成，由血液、渗出液和细胞外液形成的脉络膜-视网膜色素上皮细胞-视网膜混合物堆积导致黄斑增厚[2]。血管内皮生长因子在脉络膜新生血管形成中起重要作用[3]。因此，抗血管内皮生长因子靶向治疗湿性AMD具有显著疗效[4]。2006年美国食品与药品管理局批准雷珠单抗用于治疗湿性AMD，2012年中国国家药监局批准其用于治疗湿性AMD。本研究使用雷珠单抗治疗湿性AMD后取得较好效果，并分析视力改善与黄斑形态学变化之间的相关性，现报告如下。, http://www.100md.com(王小堂 谢安明)